Synox Therapeutics Announces Positive Topline Results From The Phase 3 TANGENT Study, Supporting Emactuzumab As A Differentiated, Next-Generation Treatment For Patients With Tenosynovial Giant Cell Tumor (TGCT)

📅 13/04/2026 02:01 📰 menafn 👁️ 5 lectures 🌍 États-Unis 📂 Santé

(MENAFN - GlobeNewsWire - Nasdaq) TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor ...